Literature DB >> 21390497

The p160 ER co-regulators predict outcome in ER negative breast cancer.

Melanie Spears1, Steffi Oesterreich, Ilenia Migliaccio, Carolina Guiterrez, Susan Hilsenbeck, Mary Anne Quintayo, Johanna Pedraza, Alison F Munro, Jeremy St J Thomas, Gill R Kerr, Wilma J L Jack, Ian H Kunkler, David A Cameron, Udi Chetty, John M S Bartlett.   

Abstract

The SRC family of ER co-regulators are frequently overexpressed in breast cancer. Overexpression of AIB1 appears to be linked to hormone resistance in HER2 positive breast cancer. However, the role of these co-regulators in ER negative disease is poorly understood. SRC1, SRC2 and AIB1 expression was determined by immunohistochemical analysis of tissue microarrays constructed from tumours within the Edinburgh Breast Conservation Series (BCS). The BCS represents a fully documented consecutive cohort of 1,812 patients treated by breast conservation surgery in a single institution. Our results demonstrate tumours that overexpress both HER2 and AIB1 were associated with markedly reduced relapse free, distant relapse free and overall survival compared to HER2 and AIB1 only overexpressing tumours irrespective of ER status. In ER negative disease both SRC1 and AIB1 were linked to early relapse and death. The SRC family of ER co-regulators is involved in early relapse and resistance in both ER negative and ER positive breast cancer challenging the conventional concept that this effect is mediated solely via the ER.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21390497     DOI: 10.1007/s10549-011-1426-1

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  5 in total

Review 1.  Derailed estrogen signaling and breast cancer: an authentic couple.

Authors:  Bramanandam Manavathi; Oindrilla Dey; Vijay Narsihma Reddy Gajulapalli; Raghavendra Singh Bhatia; Suresh Bugide; Rakesh Kumar
Journal:  Endocr Rev       Date:  2012-09-04       Impact factor: 19.871

2.  Expression of AIB1 protein as a prognostic factor in breast cancer.

Authors:  Kyungji Lee; Ahwon Lee; Byung Joo Song; Chang Suk Kang
Journal:  World J Surg Oncol       Date:  2011-10-29       Impact factor: 2.754

3.  Oestrogen receptor co-activator AIB1 is a marker of tamoxifen benefit in postmenopausal breast cancer.

Authors:  M Weiner; L Skoog; T Fornander; B Nordenskjöld; D C Sgroi; O Stål
Journal:  Ann Oncol       Date:  2013-05-12       Impact factor: 32.976

4.  Prognostic and predictive importance of the estrogen receptor coactivator AIB1 in a randomized trial comparing adjuvant letrozole and tamoxifen therapy in postmenopausal breast cancer: the Danish cohort of BIG 1-98.

Authors:  S Alkner; M-B Jensen; B B Rasmussen; P-O Bendahl; M Fernö; L Rydén; H Mouridsen
Journal:  Breast Cancer Res Treat       Date:  2017-08-01       Impact factor: 4.872

5.  The role of amplified in breast cancer 1 in breast cancer: A meta-analysis.

Authors:  Jianjing Hou; Jingting Liu; Mengci Yuan; Chunyan Meng; Jianhua Liao
Journal:  Medicine (Baltimore)       Date:  2020-11-13       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.